Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate whether exposure to metformin during the first trimester of pregnancy, for diabetes or other indications, increases the risk of all or specific congenital anomalies. DESIGN: Population based exploratory case-control study using malformed controls. Cases of 29 specific subgroups of non-genetic anomalies, and all non-genetic anomalies combined, were compared with controls (all other non-genetic anomalies or genetic syndromes). SETTING: 11 EUROmediCAT European congenital anomaly registries surveying 1 892 482 births in Europe between 2006 and 2013. PARTICIPANTS: 50 167 babies affected by congenital anomaly (41 242 non-genetic and 8925 genetic) including live births, fetal deaths from 20 weeks' gestation, and terminations of pregnancy for fetal anomaly. MAIN OUTCOME MEASURE: Odds ratios adjusted for maternal age, registry, multiple birth, and maternal diabetes status. RESULTS: 168 babies affected by congenital anomaly (141 non-genetic and 27 genetic) were exposed to metformin, 3.3 per 1000 births. No evidence was found for a higher proportion of exposure to metformin during the first trimester among babies with all non-genetic anomalies combined compared with genetic controls (adjusted odds ratio 0.84, 95% confidence interval 0.55 to 1.30). The only significant result was for pulmonary valve atresia (adjusted odds ratio 3.54, 1.05 to 12.00, compared with non-genetic controls; 2.86, 0.79 to 10.30, compared with genetic controls). CONCLUSIONS: No evidence was found for an increased risk of all non-genetic congenital anomalies combined following exposure to metformin during the first trimester, and the one significant association was no more than would be expected by chance. Further surveillance is needed to increase sample size and follow up the cardiac signal, but these findings are reassuring given the increasing use of metformin in pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Criteria, Prevalence, and Phenotypes of Polycystic Ovary Syndrome
Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.05.003 · Cited by 1,358
Rothman, K. J., Greenland, S., & Lash, T. L. (2008) · Encyclopedia of Quantitative Risk Analysis and Assessment · doi:10.1002/9780470061596.risk0599 · Cited by 706
Valproic Acid Monotherapy in Pregnancy and Major Congenital Malformations
Jentink, J., Loane, M. A., Dolk, H., Barisic, I., Garne, E., Morris, J. K., & de Jong-van den Berg, L. T. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907328 · Cited by 587
Self-citationMetformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)
Rowan, J. A., Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Hague, W. M. (2011) · Diabetes Care · doi:10.2337/dc11-0660 · Cited by 379
Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis
Gilbert, C., Valois, M., & Koren, G. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.02.098 · Cited by 274
Placental passage of metformin in women with polycystic ovary syndrome
Vanky, E., Zahlsen, K., Spigset, O., & Carlsen, S. M. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.051 · Cited by 245
Cassina, M., Donà, M., Di Gianantonio, E., Litta, P., & Clementi, M. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu022 · Cited by 143
Cited by
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Gestational diabetes mellitus: mechanisms, treatment, and complications
Johns, E. C., Denison, F. C., Norman, J. E., & Reynolds, R. M. (2018) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2018.09.004 · Cited by 828
ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002960 · Cited by 470
Løvvik, T. S., Carlsen, S. M., Salvesen, Ø., Steffensen, B., Bixo, M., Gómez-Real, F., Lønnebotn, M., Hestvold, K. V., Zabielska, R., Hirschberg, A. L., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30002-6 · Cited by 176
Hanem, L. G. E., Salvesen, Ø., Juliusson, P. B., Carlsen, S. M., Nossum, M. C. F., Vaage, M. Ø., Ødegård, R., & Vanky, E. (2019) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30385-7 · Cited by 134
Hedermann, G., Hedley, P. L., Thagaard, I. N., Krebs, L., Ekelund, C. K., Sørensen, T. I. A., & Christiansen, M. (2021) · PLOS ONE · doi:10.1371/journal.pone.0252343 · Cited by 48
“either metformin or beta-blockers during pregnancy may actually increase the risk of certain types of CHDs in the foetus [20, 79].”
BackgroundMetformin for gestational diabetes mellitus: progeny, perspective, and a personalized approach
Barbour, L. A., & Feig, D. S. (2019) · Diabetes Care · doi:10.2337/dci18-0055 · Cited by 44
Metadata
- Authors
- Given, J. E., Loane, M., Garne, E., Addor, M.-C., Bakker, M., Bertaut-Nativel, B., Gatt, M., Klungsoyr, K., Lelong, N., Morgan, M., Neville, A. J., Pierini, A., Rissmann, A., & Dolk, H.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2018-06-25
- Volume
- 361
- Pages
- k2477
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2808783993
- Cited by
- 130
- References
- 15
- FWCI
- 18.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.